Skip to main content
Top
Published in: PharmacoEconomics - Open 5/2023

Open Access 26-06-2023 | Platelet Transfusion | Systematic Review

Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review

Authors: Jorien Laermans, Hans Van Remoortel, Hans Scheers, Bert Avau, Jørgen Georgsen, Susan Nahirniak, Nadine Shehata, Simon J. Stanworth, Emmy De Buck, Veerle Compernolle, Philippe Vandekerckhove

Published in: PharmacoEconomics - Open | Issue 5/2023

Login to get access

Abstract

Background and Objective

Evidence-based guidelines on platelet transfusion therapy assist clinicians to optimize patient care, but currently do not take into account costs associated with different methods used during the preparation, storage, selection and dosing of platelets for transfusion. This systematic review aimed to summarize the available literature regarding the cost effectiveness (CE) of these methods.

Methods

Eight databases and registries, as well as 58 grey literature sources, were searched up to 29 October 2021 for full economic evaluations comparing the CE of methods for preparation, storage, selection and dosing of allogeneic platelets intended for transfusion in adults. Incremental CE ratios, expressed as standardized cost (in 2022 EUR) per quality-adjusted life-year (QALY) or per health outcome, were synthesized narratively. Studies were critically appraised using the Philips checklist.

Results

Fifteen full economic evaluations were identified. Eight investigated the costs and health consequences (transfusion-related events, bacterial and viral infections or illnesses) of pathogen reduction. The estimated incremental cost per QALY varied widely from EUR 259,614 to EUR 36,688,323. For other methods, such as pathogen testing/culturing, use of apheresis instead of whole blood-derived platelets, and storage in platelet additive solution, evidence was sparse. Overall, the quality and applicability of the included studies was limited.

Conclusions

Our findings are of interest to decision makers who consider implementing pathogen reduction. For other preparation, storage, selection and dosing methods in platelet transfusion, CE remains unclear due to insufficient and outdated evaluations. Future high-quality research is needed to expand the evidence base and increase our confidence in the findings.
Appendix
Available only for authorised users
Literature
1.
go back to reference FDA. Bacterial Risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion—guidance for Industry2020 December 2020. FDA. Bacterial Risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion—guidance for Industry2020 December 2020.
2.
go back to reference Saris A, Pavenski K. Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness. Transfus Med Rev. 2020;34(4):250–7.CrossRefPubMed Saris A, Pavenski K. Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness. Transfus Med Rev. 2020;34(4):250–7.CrossRefPubMed
3.
go back to reference Kreuger AL, Caram-Deelder C, Jacobse J, Kerkhoffs JL, van der Bom JG, Middelburg RA. Effect of storage time of platelet products on clinical outcomes after transfusion: a systematic review and meta-analyses. Vox Sang. 2017;112(4):291–300.CrossRefPubMed Kreuger AL, Caram-Deelder C, Jacobse J, Kerkhoffs JL, van der Bom JG, Middelburg RA. Effect of storage time of platelet products on clinical outcomes after transfusion: a systematic review and meta-analyses. Vox Sang. 2017;112(4):291–300.CrossRefPubMed
4.
go back to reference van der Meer PF, de Korte D. Platelet additive solutions: a review of the latest developments and their clinical implications. Transfus Med Hemother. 2018;45(2):98–102.CrossRefPubMedPubMedCentral van der Meer PF, de Korte D. Platelet additive solutions: a review of the latest developments and their clinical implications. Transfus Med Hemother. 2018;45(2):98–102.CrossRefPubMedPubMedCentral
5.
go back to reference Nahirniak S, Slichter SJ, Tanael S, Rebulla P, Pavenski K, Vassallo R, et al. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. Transfus Med Rev. 2015;29(1):3–13.CrossRefPubMed Nahirniak S, Slichter SJ, Tanael S, Rebulla P, Pavenski K, Vassallo R, et al. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. Transfus Med Rev. 2015;29(1):3–13.CrossRefPubMed
6.
go back to reference Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K. ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion. 2009;49(11):2442–53.CrossRefPubMed Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K. ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion. 2009;49(11):2442–53.CrossRefPubMed
7.
go back to reference Estcourt LJ, Stanworth S, Doree C, Trivella M, Hopewell S, Blanco P, et al. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015;10:CD010984. Estcourt LJ, Stanworth S, Doree C, Trivella M, Hopewell S, Blanco P, et al. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015;10:CD010984.
8.
go back to reference Estcourt LJ, Birchall J, Allard S, Bassey SJ, Hersey P, Kerr JP, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176(3):365–94.CrossRefPubMed Estcourt LJ, Birchall J, Allard S, Bassey SJ, Hersey P, Kerr JP, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176(3):365–94.CrossRefPubMed
9.
go back to reference Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–13.CrossRefPubMed Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–13.CrossRefPubMed
10.
go back to reference Avau B, O D, Veys K, Georgsen J, Nahirniak S, Shehata N, et al. Systematic reviews on platelet transfusions—is there unnecessary duplication of effort? A scoping review. Vox Sanguinis [in revision]. 2022. Avau B, O D, Veys K, Georgsen J, Nahirniak S, Shehata N, et al. Systematic reviews on platelet transfusions—is there unnecessary duplication of effort? A scoping review. Vox Sanguinis [in revision]. 2022.
13.
go back to reference Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36):iii–iv (ix-xi, 1-158).CrossRefPubMed Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36):iii–iv (ix-xi, 1-158).CrossRefPubMed
14.
go back to reference Mandrik OL, Severens JLH, Bardach A, Ghabri S, Hamel C, Mathes T, et al. Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR Good Practices Task Force Report. Value Health. 2021;24(4):463–72.CrossRefPubMed Mandrik OL, Severens JLH, Bardach A, Ghabri S, Hamel C, Mathes T, et al. Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR Good Practices Task Force Report. Value Health. 2021;24(4):463–72.CrossRefPubMed
15.
go back to reference Agapova M, Busch MP, Custer B. Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi. Transfusion. 2010;50(10):2220–32.CrossRefPubMed Agapova M, Busch MP, Custer B. Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi. Transfusion. 2010;50(10):2220–32.CrossRefPubMed
16.
go back to reference Balducci L, Benson K, Lyman GH, Sanderson R, Fields K, Ballester OF, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion. 1993;33(8):665–70.CrossRefPubMed Balducci L, Benson K, Lyman GH, Sanderson R, Fields K, Ballester OF, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion. 1993;33(8):665–70.CrossRefPubMed
17.
go back to reference Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther. 2003;25(9):2464–86.CrossRefPubMedPubMedCentral Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther. 2003;25(9):2464–86.CrossRefPubMedPubMedCentral
18.
go back to reference Bloch EM, Marshall CE, Boyd JS, Shifflett L, Tobian AAR, Gehrie EA, et al. Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions. Transfusion. 2018;58(7):1647–53.CrossRefPubMed Bloch EM, Marshall CE, Boyd JS, Shifflett L, Tobian AAR, Gehrie EA, et al. Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions. Transfusion. 2018;58(7):1647–53.CrossRefPubMed
19.
go back to reference Blumberg N, Heal JM. Mortality risks, costs, and decision making in transfusion medicine. Am J Clin Pathol. 2000;114(6):934–7.CrossRefPubMed Blumberg N, Heal JM. Mortality risks, costs, and decision making in transfusion medicine. Am J Clin Pathol. 2000;114(6):934–7.CrossRefPubMed
20.
go back to reference Kacker S, Ness PM, Savage WJ, Frick KD, McCullough J, King KE, et al. The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions. Transfusion. 2013;53(11):2609–18.CrossRefPubMedPubMedCentral Kacker S, Ness PM, Savage WJ, Frick KD, McCullough J, King KE, et al. The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions. Transfusion. 2013;53(11):2609–18.CrossRefPubMedPubMedCentral
21.
go back to reference Lopez-Plaza I, Weissfeld J, Triulzi DJ. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion. 1999;39(9):925–32.CrossRefPubMed Lopez-Plaza I, Weissfeld J, Triulzi DJ. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion. 1999;39(9):925–32.CrossRefPubMed
22.
go back to reference McFarland JG, Larson EB, Hillman RS, Slichter SJ. Cost-benefit analysis of a plateletapheresis program. Transfusion. 1986;26(1):91–7.CrossRefPubMed McFarland JG, Larson EB, Hillman RS, Slichter SJ. Cost-benefit analysis of a plateletapheresis program. Transfusion. 1986;26(1):91–7.CrossRefPubMed
23.
go back to reference Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion. 2010;50(11):2461–73.CrossRefPubMed Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion. 2010;50(11):2461–73.CrossRefPubMed
24.
go back to reference Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion. 2006;46(6):956–65.CrossRefPubMed Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion. 2006;46(6):956–65.CrossRefPubMed
25.
go back to reference Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med. 2005;15(5):379–87.CrossRefPubMed Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med. 2005;15(5):379–87.CrossRefPubMed
26.
go back to reference Moeremans K, Warie H, Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med. 2006;16(1):17–30.CrossRefPubMed Moeremans K, Warie H, Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med. 2006;16(1):17–30.CrossRefPubMed
27.
go back to reference Agapova M, Lachert E, Brojer E, Letowska M, Grabarczyk P, Custer B. Introducing pathogen reduction technology in Poland: a cost-utility analysis. Transfus Med Hemother. 2015;42(3):158–65.CrossRefPubMedPubMedCentral Agapova M, Lachert E, Brojer E, Letowska M, Grabarczyk P, Custer B. Introducing pathogen reduction technology in Poland: a cost-utility analysis. Transfus Med Hemother. 2015;42(3):158–65.CrossRefPubMedPubMedCentral
28.
go back to reference SaBTO. Pathogen inactivation of platelets—Report of the SaBTO Working Group2014. SaBTO. Pathogen inactivation of platelets—Report of the SaBTO Working Group2014.
29.
go back to reference Staginnus U, Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol. 2004;80(4):317–24.CrossRefPubMed Staginnus U, Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol. 2004;80(4):317–24.CrossRefPubMed
31.
go back to reference Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1(1):8.CrossRefPubMedPubMedCentral Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1(1):8.CrossRefPubMedPubMedCentral
32.
go back to reference Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43(6):721–9.CrossRefPubMed Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43(6):721–9.CrossRefPubMed
33.
go back to reference Yeh JM, Botteman M, Pashos CL, Postma MJ, Staginnus U. Economics of transfusion. Infusion Therapy Transfus Med-Infusionstherapie und transfusionsmedizin. 2002;29(4):218–25. Yeh JM, Botteman M, Pashos CL, Postma MJ, Staginnus U. Economics of transfusion. Infusion Therapy Transfus Med-Infusionstherapie und transfusionsmedizin. 2002;29(4):218–25.
34.
go back to reference Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, Fink A, Brook R. The cost effectiveness of preoperative autologous blood donations. N Engl J Med. 1995;332(11):719–24. Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, Fink A, Brook R. The cost effectiveness of preoperative autologous blood donations. N Engl J Med. 1995;332(11):719–24.
Metadata
Title
Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review
Authors
Jorien Laermans
Hans Van Remoortel
Hans Scheers
Bert Avau
Jørgen Georgsen
Susan Nahirniak
Nadine Shehata
Simon J. Stanworth
Emmy De Buck
Veerle Compernolle
Philippe Vandekerckhove
Publication date
26-06-2023
Publisher
Springer International Publishing
Published in
PharmacoEconomics - Open / Issue 5/2023
Print ISSN: 2509-4262
Electronic ISSN: 2509-4254
DOI
https://doi.org/10.1007/s41669-023-00427-w

Other articles of this Issue 5/2023

PharmacoEconomics - Open 5/2023 Go to the issue